Xxpinxxharxxceuxxcalxxinc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Xxpinxxharxxceuxxcalxxinc Pharmaceutical Import Records from India — 2 Products, $950.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Xxpinxxharxxceuxxcalxxinc — Pharmaceutical Importer Profile (2026) | 2 Products, $950.0K Trade | TransData Nexus

Xxpinxxharxxceuxxcalxxinc

Pharmaceutical Importer · United States · Cardiovascular Focus · $950.0K Total Trade · DGFT Verified

Xxpinxxharxxceuxxcalxxinc is a pharmaceutical importer based in United States with a total trade value of $950.0K across 2 products in 2 therapeutic categories. Based on 19 verified import shipments from Indian Customs (DGFT) records, Xxpinxxharxxceuxxcalxxinc is the #1 buyer in 1 product including Darunavir. Xxpinxxharxxceuxxcalxxinc sources from 1 verified Indian supplier, with Lupin Limited accounting for 100.0% of imports.

Xxpinxxharxxceuxxcalxxinc — Import Portfolio & Supplier Network

Xxpinxxharxxceuxxcalxxinc import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Xxpinxxharxxceuxxcalxxinc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Lupin Limited	$3.9M	89	100.0%

Xxpinxxharxxceuxxcalxxinc sources from 1 verified Indian supplier across 58 distinct formulations. The sourcing is highly concentrated — Lupin Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Xxpinxxharxxceuxxcalxxinc Import?

Formulation	Value	Ships
Lisinopril TAB USP 5MG-1000's(us).	$226.4K	5
Turqoz (0.3MG/0.03MG)3x28 TAB	$194.6K	4
Lisinopril&hctz TAB USP 20/12.5MG-100's.	$150.0K	3
Leflunomide TAB 20MG x 30's	$139.3K	4
Sertraline TAB USP 100MG-90's(us).	$128.9K	3
Lisinopril&hctz TAB USP 20/25MG-100's.	$100.0K	2
Sertraline TAB USP 50MG-500's(us).	$100.0K	2
Sertraline TAB USP 100MG-500's(us).	$100.0K	2
Fenofibrate TAB USP 145MG 90s uncoat	$100.0K	2
Divalproex sod er TAB 500MG x 500's us.	$100.0K	2
Norethindrone tabs USP 0.35MG	$100.0K	2
Lurasidone hcl tabs 80MG x 30's us.	$100.0K	2
Dros&ee TAB USP 3/0.03MG 3x28s_eq	$100.0K	2
Divalproex sod er TAB 500MG x 100's us.	$99.1K	2
Divalproex sod er TAB 250MG x 100's us.	$80.8K	2

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Lisinopril	Cardiovascular	$850.0K	17	1.4%	4
2	Darunavir	Antiviral & HIV Medications	$100.0K	2	0.2%	1

Xxpinxxharxxceuxxcalxxinc imports 2 pharmaceutical products across 2 categories into United States totaling $950.0K. The company is the #1 buyer for 1 product: Darunavir.

Xxpinxxharxxceuxxcalxxinc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Xxpinxxharxxceuxxcalxxinc is a United States-based pharmaceutical importer specializing in the acquisition of finished pharmaceutical formulations from international suppliers. Operating as a buyer, the company plays a pivotal role in sourcing and importing pharmaceutical products to meet the demands of the U.S. market. While specific details about its headquarters and parent company are not publicly disclosed, its operations are integral to the U.S. pharmaceutical distribution network. By importing a diverse range of pharmaceutical products, Xxpinxxharxxceuxxcalxxinc contributes to the availability and accessibility of essential medications across the country.

2Distribution Network

Xxpinxxharxxceuxxcalxxinc's distribution network encompasses a range of logistics capabilities designed to ensure the efficient delivery of pharmaceutical products throughout the United States. While specific warehouse locations are not publicly disclosed, the company's operations are likely supported by strategically located facilities that facilitate timely and compliant distribution. The logistics infrastructure is designed to handle the complexities of pharmaceutical imports, including adherence to regulatory requirements and maintenance of product integrity during transit. This network enables Xxpinxxharxxceuxxcalxxinc to serve a broad geographic area, ensuring that imported pharmaceutical products are accessible to various stakeholders within the U.S. healthcare system.

3Industry Role

In the U.S. pharmaceutical supply chain, Xxpinxxharxxceuxxcalxxinc functions primarily as a pharmaceutical importer and buyer. By sourcing finished pharmaceutical formulations from international suppliers, the company acts as an intermediary between foreign manufacturers and the U.S. market. This role is crucial in ensuring the availability of a diverse array of pharmaceutical products, including those not readily produced domestically. Xxpinxxharxxceuxxcalxxinc's activities support various segments of the U.S. healthcare system, including retail pharmacies, hospitals, and clinics, by providing access to essential medications that meet regulatory standards and patient needs.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Xxpinxxharxxceuxxcalxxinc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Xxpinxxharxxceuxxcalxxinc demonstrates a high degree of sourcing concentration, with all 19 shipments from India originating from a single supplier, Lupin Limited. This exclusive sourcing strategy indicates a strategic partnership, potentially offering benefits such as favorable pricing, consistent product quality, and reliable supply chain management. However, this single-source dependency also introduces risks, including vulnerability to supply disruptions, regulatory changes affecting the supplier, or geopolitical factors impacting trade relations. The absence of alternative suppliers may limit the company's flexibility in responding to market fluctuations or supply chain challenges. Therefore, while the concentrated sourcing approach may streamline operations, it is essential for Xxpinxxharxxceuxxcalxxinc to assess and mitigate potential risks associated with this dependency.

2Supply Chain Resilience

Xxpinxxharxxceuxxcalxxinc's supply chain resilience is closely tied to its exclusive relationship with Lupin Limited, a leading global pharmaceutical manufacturer headquartered in Mumbai, India. Lupin Limited has demonstrated a strong commitment to quality and compliance, as evidenced by the successful outcomes of U.S. FDA inspections at its facilities, including the Somerset facility in New Jersey in February 2025 and the Nagpur Unit-1 facility in November 2025. These inspections concluded with zero 483 observations, underscoring Lupin's adherence to stringent regulatory standards. The alignment between Xxpinxxharxxceuxxcalxxinc and Lupin Limited suggests a robust supply chain capable of maintaining product quality and regulatory compliance. However, the lack of backup suppliers and the exclusive nature of the sourcing arrangement may expose Xxpinxxharxxceuxxcalxxinc to risks associated with supply chain disruptions. To enhance resilience, it would be prudent for the company to consider diversifying its supplier base and establishing contingency plans to address potential challenges.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act, which establishes the legal framework for drug approval, manufacturing, and importation. Pharmaceutical imports must comply with FDA regulations, including registration and listing requirements, to ensure product safety, efficacy, and quality. For foreign manufacturers, such as Lupin Limited, this involves registering their establishments with the FDA and listing all drugs intended for commercial distribution in the U.S. market. Additionally, the FDA requires that imported drugs have an approved marketing application, such as a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA), to be legally marketed in the U.S.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are stringent. Foreign drug establishments must register with the FDA and list all drugs intended for importation. This process ensures that imported drugs meet U.S. standards for safety, efficacy, and quality. Good Manufacturing Practice (GMP) certification is a critical component of this process. The FDA recognizes GMP certifications from various international standards, including EU GMP, WHO GMP, and PIC/S. For Indian exporters, obtaining GMP certification from recognized bodies is essential to facilitate the importation of their products into the U.S. market. Additionally, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products within the U.S., ensuring compliance with federal and state regulations.

Xxpinxxharxxceuxxcalxxinc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Xxpinxxharxxceuxxcalxxinc's product strategy focuses on importing pharmaceutical formulations in the cardiovascular and antiviral therapeutic categories. The company's portfolio is heavily weighted towards cardiovascular medications, with lisinopril accounting for a significant portion of the import value. This focus aligns with the high demand for cardiovascular drugs in the U.S. market, driven by the prevalence of heart-related conditions among the population. The inclusion of antiviral medications, such as darunavir, addresses the ongoing need for HIV treatments, reflecting the company's commitment to providing essential therapies for chronic conditions. By concentrating on these therapeutic areas, Xxpinxxharxxceuxxcalxxinc aims to meet critical healthcare needs and capitalize on market opportunities within the U.S. pharmaceutical sector.

2Sourcing Profile

Xxpinxxharxxceuxxcalxxinc's sourcing strategy is centered on procuring generic drug formulations from Lupin Limited, a leading Indian pharmaceutical manufacturer. The company's preference for finished pharmaceutical formulations indicates a focus on ready-to-market products that comply with U.S. regulatory standards. India's robust pharmaceutical industry, characterized by its adherence to international GMP standards and a diverse product portfolio, positions it as a strategic sourcing partner for Xxpinxxharxxceuxxcalxxinc. By leveraging India's manufacturing capabilities, the company can access a wide range of pharmaceutical products that meet the quality and compliance requirements of the U.S. market.

Frequently Asked Questions — Xxpinxxharxxceuxxcalxxinc

What products does Xxpinxxharxxceuxxcalxxinc import from India?

Xxpinxxharxxceuxxcalxxinc imports 2 pharmaceutical products across 2 categories. Top imports: Lisinopril ($850.0K), Darunavir ($100.0K).

Who supplies pharmaceuticals to Xxpinxxharxxceuxxcalxxinc from India?

Xxpinxxharxxceuxxcalxxinc sources from 1 verified Indian suppliers. The primary supplier is Lupin Limited (100.0% of imports, $3.9M).

What is Xxpinxxharxxceuxxcalxxinc's total pharmaceutical import value?

Xxpinxxharxxceuxxcalxxinc's total pharmaceutical import value from India is $950.0K, based on 19 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Xxpinxxharxxceuxxcalxxinc focus on?

Xxpinxxharxxceuxxcalxxinc imports across 2 categories. The largest: Cardiovascular (89.5%), Antiviral & HIV Medications (10.5%).

Get Full Xxpinxxharxxceuxxcalxxinc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.